筛查与三级转诊中心乳腺超声筛查BI-RADS 3病变的随访间隔
研究纳入1451例乳腺X线筛查阴性或良性、超声筛查BI-RADS 3的无症状女性,中位随访30.8个月。筛查中心与三级中心恶性率均为1.3%(9/699 vs 10/752),筛查中心9例均为浸润癌且12.3个月后诊断,三级中心2例于6个月诊断。作者认为筛查中心宜1年随访而非6个月,三级中心6个月随访可能更合适。
要点
- 筛查中心超声筛查BI-RADS 3病变恶性率1.3%(9/699),均为浸润癌且12.3个月后诊断。
- 三级中心超声筛查BI-RADS 3病变恶性率1.3%(10/752),含2例导管原位癌、8例浸润癌。
- 三级中心2例浸润癌于6个月诊断,余8例于13.1个月后新发。
核心结论
- 筛查中心超声筛查发现的BI-RADS 3病变,1年随访可能比6个月随访更合适。
- 三级中心类似发现需更多警惕,6个月随访可能更合适。
研究设计与样本
- 研究纳入1451例乳腺X线筛查阴性或良性、超声筛查BI-RADS 3且随访至少6个月的无症状女性。
- 中位随访间隔30.8个月(范围6.8-52.9个月)。
- 比较筛查中心与三级中心的癌检出率、检出时间点、危险因素及临床病理特征。
- 名义变量用卡方检验或Fisher精确检验,连续变量用独立t检验或Mann-Whitney U检验。
诊断标准与关键数值
- 总体1451例中检出19例癌(1.3%),其中2例(0.1%)于6个月诊断,17例(1.2%)于12.3个月后诊断。
- 筛查中心恶性率1.3%(9/699),三级中心恶性率1.3%(10/752)。
- 筛查中心9例均为浸润癌,均于12.3个月后诊断。
- 三级中心2例为导管原位癌、8例为浸润癌;其中2例浸润癌于6个月诊断,余8例于13.1个月后新发。
临床应用与阅片要点
- 筛查中心超声筛查BI-RADS 3病变可考虑1年随访而非6个月。
- 三级中心类似BI-RADS 3发现需更多警惕,6个月随访可能更合适。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To assess the appropriate follow-up interval, and rate and timepoint of cancer detection in women with Breast Imaging Reporting and Data System (BI-RADS) 3 lesions on screening ultrasonography (US) according to the type of institution.
MATERIALS AND METHODS: A total of 1451 asymptomatic women who had negative or benign findings on screening mammogram, BI-RADS 3 assessment on screening US, and at least 6 months of follow-up were included. The median follow-up interval was 30.8 months (range, 6.8-52.9 months). The cancer detection rate, cancer detection timepoint, risk factors, and clinicopathological characteristics were compared between the screening and tertiary centers. Nominal variables were compared using the chi-square or Fisher's exact test and continuous variables were compared using the independent t test or Mann-Whitney U test.
RESULTS: In 1451 women, 19 cancers (1.3%) were detected; two (0.1%) were diagnosed at 6 months and 17 (1.2%) were diagnosed after 12.3 months. The malignancy rates were both 1.3% in the screening (9 of 699) and tertiary (10 of 752) centers. In the screening center, all nine cancers were invasive cancers and diagnosed after 12.3 months. In the tertiary center, two were ductal carcinomas in situ and eight were invasive cancers. Two of the invasive cancers were diagnosed at 6 months and the remaining eight cancers newly developed after 13.1 months.
CONCLUSION: One-year follow-up rather than 6-month follow-up may be suitable for BI-RADS 3 lesions on screening US found in screening centers. However, more caution is needed regarding similar findings in tertiary centers where 6-month follow-up may be more appropriate.
引用
- Huh S, Suh HJ, Kim EK, et al. Follow-Up Intervals for Breast Imaging Reporting and Data System Category 3 Lesions on Screening Ultrasound in Screening and Tertiary Referral Centers. Korean J Radiol. 2020. PMID: 32691538. doi:10.3348/kjr.2019.0747
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。